Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BTX-6654 |
Synonyms | |
Therapy Description |
BTX-6654 is a bifunctional SOS1 degrader that potentially decreases downstream KRAS signaling and inhibits tumor growth (PMID: 38224565). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BTX-6654 | BTX6654|BTX 6654 | SOS1 Inhibitor 16 | BTX-6654 is a bifunctional SOS1 degrader that potentially decreases downstream KRAS signaling and inhibits tumor growth (PMID: 38224565). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
HRAS Q61H | uterine cancer | sensitive | BTX-6654 | Preclinical - Cell culture | Actionable | In a preclinical study, BTX-6654 inhibited proliferation of a uterine cancer cell line harboring HRAS Q61H in 3D culture (PMID: 38224565). | 38224565 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|